AlloCAR-NKT cells could deploy CAR/TCR/NKR triple-targeting mechanisms, suitable for CD1d+ tumors, such as certain types of blood cancer (for example, MM, acute myeloid leukemia and myelomonocytic leukemia) and some solid tumors (for example, medulloblastoma and glioblastoma) (Fig. 2a)18. The gene discussed is CD1D; the disease is acute myeloid leukemia.